Resveratrol in primary and secondary prevention of cardiovascular disease: a dietary and clinical perspective. (Q34357562)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23855464%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

Resveratrol in primary and secondary prevention of cardiovascular disease: a dietary and clinical perspective (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23855464%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

main subject

cardiovascular disease

1 reference

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23855464%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

João Tomé-Carneiro

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23855464%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Mar Larrosa

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23855464%20AND%20SRC:MED&resulttype=core&format=json

María-Teresa García-Conesa

5 March 2020

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23855464%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

Manuel Gonzálvez

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23855464%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

María J Yáñez-Gascón

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23855464%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Francisco J García-Almagro

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23855464%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

José A Ruiz-Ros

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23855464%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Francisco A Tomás-Barberán

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23855464%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

language of work or name

English

0 references

publication date

1 July 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23855464%20AND%20SRC:MED&resulttype=core&format=json

Annals of the New York Academy of Sciences

5 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23855464%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

1290

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23855464%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

37-51

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23855464%20AND%20SRC:MED&resulttype=core&format=json

What is new for an old molecule? Systematic review and recommendations on the use of resveratrol

5 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Postharvest induction modeling method using UV irradiation pulses for obtaining resveratrol-enriched table grapes: a new "functional" fruit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

A review of the content of the putative chemopreventive phytoalexin resveratrol in red wine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Colon cancer stem cells: implications in carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Resveratrol, pterostilbene, and piceatannol in vaccinium berries

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Determination of the phytoalexin resveratrol (3,5,4'-trihydroxystilbene) in peanuts and pistachios by high-performance liquid chromatographic diode array (HPLC-DAD) and gas chromatography-mass spectrometry (GC-MS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Wine, alcohol, platelets, and the French paradox for coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Involvement of breast cancer resistance protein (BCRP1/ABCG2) in the bioavailability and tissue distribution of trans-resveratrol in knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Intestinal breast cancer resistance protein (BCRP)/Bcrp1 and multidrug resistance protein 3 (MRP3)/Mrp3 are involved in the pharmacokinetics of resveratrol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Multidrug resistance proteins restrain the intestinal absorption of trans-resveratrol in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Enhancing the bioavailability of resveratrol by combining it with piperine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Optimization of trans-Resveratrol bioavailability for human therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Atherosclerosis — An Inflammatory Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Inflammation, atherosclerosis, and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Resveratrol: a cardioprotective substance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Resveratrol in cardiovascular disease: what is known from current research?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Animal models for the atherosclerosis research: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Resveratrol improves myocardial perfusion in a swine model of hypercholesterolemia and chronic myocardial ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Resveratrol modifies risk factors for coronary artery disease in swine with metabolic syndrome and myocardial ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Resveratrol preserves myocardial function and perfusion in remote nonischemic myocardium in a swine model of metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

A dietary resveratrol-rich grape extract prevents the developing of atherosclerotic lesions in the aorta of pigs fed an atherogenic diet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Effects of long-term consumption of low doses of resveratrol on diet-induced mild hypercholesterolemia in pigs: a transcriptomic approach to disease prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Pilot study of resveratrol in older adults with impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: effects on lipid profiles, inflammation markers, and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Postharvest stilbene-enrichment of red and white table grape varieties using UV-C irradiation pulses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Relation of C-reactive protein to endothelial fibrinolytic function in healthy adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

The protective effect of the Mediterranean diet: focus on cancer and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Atorvastatin administration after percutaneous coronary intervention in patients with coronary artery disease and normal lipid profiles: impact on plasma adiponectin level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Plasminogen-activator inhibitor type 1 and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Role of FoxO1 in FFA-induced oxidative stress in adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

The use of ω-3 poly-unsaturated fatty acids in heart failure: a preferential role in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Statin regulation of CYP3A4 and CYP3A5 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

The bioavailability and distribution of trans-resveratrol are constrained by ABC transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Athe

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

The role of niacin in lipid-lowering treatment: are we aiming too high?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Metabolites and tissue distribution of resveratrol in the pig

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150

Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: A triple-blind, 6-month follow-up, placebo-controlled, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12150